---
title: "ARCH Venture Partners X Discloses 12.9% Stake in Aspen Neuroscience"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304929595.md"
description: "ARCH Venture Partners X disclosed a 12.9% stake in Aspen Neuroscience, Inc., holding 3,754,922 common shares. The acquisition included 1,333,333 IPO shares purchased at $15 each on Nov. 2, 2026. ARCH stated the investment is for financial purposes and has no current plans to alter Aspen Neuroscience's business operations, board composition, or ownership structure."
datetime: "2026-11-10T00:36:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304929595.md)
  - [en](https://longbridge.com/en/news/304929595.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304929595.md)
generator: "portal-rs"
---

# ARCH Venture Partners X Discloses 12.9% Stake in Aspen Neuroscience

**ARCH Venture Partners X Discloses 12.9% Stake in Aspen Neuroscience**

ARCH Venture Partners X, LLC and affiliated funds reported a combined 12.9% ownership stake in Aspen Neuroscience, Inc., equal to 3,754,922 common shares. On Nov. 2, 2026, ARCH Venture Fund X, ARCH Venture Fund X Overage and ARCH Venture Fund XIV bought a combined 1,333,333 IPO shares at $15 apiece. The group says it holds the shares for investment and disclosed no present plans for changes to Aspen Neuroscience's business or control.

**Investor Intent**

The ARCH funds say they acquired the shares for investment purposes and have no present plans that would change Aspen Neuroscience's business, board or ownership structure. They could buy or sell additional shares in the future, but they disclosed no specific next step.

**Investor's Background**

ARCH Venture Partners X, LLC is a Delaware limited liability company that serves as general partner to ARCH Venture Partners X, L.P. and ARCH Venture Partners X Overage, L.P. Those partnerships serve as general partners to ARCH Venture Fund X and ARCH Venture Fund X Overage. The filing describes the ARCH committee members as investment committee members who also work with affiliated partnerships.

Original SEC Filing: Aspen Neuroscience, Inc. \[ ASPE \] - SCHEDULE 13D - Nov. 09, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ASPE.US](https://longbridge.com/en/quote/ASPE.US.md)

## Related News & Research

- [OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake](https://longbridge.com/en/news/304700413.md)
- [ARCH Venture Fund XIV Reports Acquisition of $18 Million in Aspen Neuroscience Common Shares](https://longbridge.com/en/news/304042044.md)
- [Aspen Neuroscience's Amended Bylaws Take Effect at IPO Closing](https://longbridge.com/en/news/304014788.md)
- [OrbiMed Advisors reports acquisition of $15 million in Aspen Neuroscience common shares](https://longbridge.com/en/news/304354913.md)
- [Coatue Raises Share Stake In Microsoft, Nvidia, Intel and SpaceX](https://longbridge.com/en/news/305663248.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**